Greeneville

Researchers are studying the effects of dalcetrapib on cardiovascular risk in people who were recently hospitalized for acute coronary syndrome (ACS) and have a specific genetic profile (AA genotype). This phase 3, randomized, double-blind, placebo-controlled study aims to understand how this drug may impact the risk of heart-related events in this group. Participants will be screened based on their medical history and genetic testing to confirm eligibility. Participants will be randomly assigned to receive either dalcetrapib 600 mg daily (two 300 mg tablets) or matching placebo tablets once a day. The study will continue until about 200 participants have experienced a primary cardiovascular event or until a planned interim analysis stops the trial. After randomization, follow-up visits will occur every three months, often virtually when possible. During the study, participants will be monitored through medical assessments, including genetic testing, and virtual or clinic visits every three months. Researchers will measure the time to the first fatal or non-fatal heart attack over an average of 30 months from randomization. Secondary measures include death, cardiac arrest, stroke, and heart attacks. If a participant stops taking the study medication early, assessments will continue every three months to collect important study data.